SLC22A1 is the gene responsible for encoding Human Organic
Cationic Transporter 1 (hOCT1), which is among a group of three similar
transporters facilitating the uptake of numerous organic cations from the
bloodstream into epithelial cells. hOCT1 shows a tendency towards several
natural substances like dopamine, along with some medications like metformin,
cimetidine, imatinib, etc. The expression of the hOCT1 gene is a reliable
indicator of treatment response and clinical outcomes in patients before
starting therapy. Furthermore, the expression of the hOCT1 gene has been known
to influence the efficacy of imatinib therapy, with higher expression levels
correlating with improved hematological and molecular responses. This chapter
proposes that evaluating the expression levels of the hOCT1 gene can be a
useful method for predicting the effectiveness of imatinib treatment in
recently diagnosed chronic myeloid leukemia (CML) patients. Understanding the
expression patterns and polymorphisms of the hOCT1 gene could thus inform the
design of personalized therapeutic strategies tailored to individual patients
at diagnosis. This knowledge could potentially optimize treatment outcomes and
enhance the overall management of CML patients undergoing imatinib therapy.
Author(s)
Details
Namrata Bhutani
Department of Biochemistry, Dr. S.S. Tantia Medical College,
Hospital & Research Centre, Sriganganagar, Rajasthan, India.
Huda
Naaz
Department of Biochemistry, Vardhman Mahavir Medical College and
Safdarjung Hospital, New Delhi, India.
Amol
Parshuram Anbhule
Department of Biochemistry, Vardhman Mahavir Medical College and
Safdarjung Hospital, New Delhi, India.
Inderpreet
Kaur
Department of Biochemistry, M.M. College of Medical Sciences &
Research, Sadopur (Ambala), Haryana,
India.
Tejinder Singh
Department of Biochemistry, Govt. Medical College, Amritsar, Punjab, India.
Jaswant Kaur
Department of Biochemistry, Dr. S.S. Tantia Medical College, Hospital &
Research Centre, Sriganganagar,
Rajasthan, India.
Please
see the book here:- https://doi.org/10.9734/bpi/dhrni/v3/1656
No comments:
Post a Comment